Topical Bimatoprost in the Treatment of Migraine

Hall, et al. have observed retrospectively that treatment with topical prostaglandin F2 alpha
analogs (applied either to the eye or fingernail bed) significantly reduced the frequency,
severity and duration of headaches in migraine sufferers, as well as their migraine
disability assessment score (MIDAS).

This is a double-blind, placebo-controlled prospective clinical study to determine if the
effect of FDA-approved bimatoprost, a prostaglandin F2 alpha analogue, has anti-migraine
activity when administered topically to people suffering from migraine.

Inclusion Criteria:

- Diagnosis of migraines based on International Classification of Headache Disorders
(ICHD) II criteria and experiencing headaches for 4 or more days per month.

Exclusion Criteria:

- Significant liver or renal dysfunction,

- On treatment for inflammatory bowel disease, medication over-use for headaches
according to the ICHD II criteria,

- Use of antipsychotics in the past month,

- Recent (in the past six months) history of alcohol or drug abuse,

- Allergy to bimatoprost and its compounds,

- Severe comorbid psychiatric illness,

- Severe infection,

- Malignancy,

- Severe cardiovascular disease,

- Neurodegenerative disorders,

- Pregnancy and lactation, and

- Sexually active women of child bearing age who do not use any method of contraception.